Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Christoph Teichert und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Drug Monitoring, Point-of-Care Testing, Adalimumab, Infliximab. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ProciseDx.
Abstract (Originalsprache)
Background and Aims Point-of-care tests (POCT) enable immediate measurement of anti-TNF blood concentrations. This study examined the association between loss of response (LOR) to infliximab (IFX) or adalimumab (ADL) and serum concentrations measured with POCT and enzyme-linked immunosorbent assay (ELISA) in inflammatory bowel disease (IBD) patients.
Methods
Patients with IBD with stored IFX or ADL serum samples were recruited. POCT was conducted, agreement with ELISA was evaluated using Bland–Altman plots. The primary endpoint was LOR defined as change in therapy, IBD-related surgery, new actively draining fistula, and/or endoscopic deterioration. ROC curves and quartile analysis assessed the association between concentrations and LOR.
Results
A total of 176 patients were included (92 IFX/84 ADL, 154 Crohn’s disease, and 22 ulcerative colitis). Median follow-up time was 20 months (interquartile range 9-38). LOR occurred in 37/84 (44%) ADL users and 55/92 (60%) IFX users. Median serum concentrations were significantly lower in LOR patients compared with sustained response, measured by both techniques for ADL (POCT: 6.45 vs 13.48 µg/mL, P <.001; ELISA: 4.80 vs 8.80 µg/mL, P <.001) and IFX (POCT: 2.39 vs 6.50 µg/mL, P <.001; ELISA: 1.70 vs 4.40 µg/mL, P <.001). Quartile analysis revealed that higher serum concentrations were associated with maintained response. ROC curve analysis demonstrated good or excellent discrimination for POCT and ELISA in association with LOR (AUC IFX: POCT = 0.82, ELISA = 0.76; AUC ADL: POCT = 0.82, ELISA = 0.81; all P <.0001). An overestimation of serum concentrations with POCT was observed.
Conclusions
Serum ADL and IFX POCT concentrations are comparable to ELISA and associated with LOR, indicating its clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
- ProciseDx Inc., 9449 Carroll Park Drive, San Diego, CA, USA.
ORCID-Profile: Christoph Teichert, Suzanne I Anjie, Krisztina B Gecse, Geert R D'Haens
Förderung
- ProciseDx
Zitieren
APA
Teichert, C., Anjie, S. I., Stevens, T. W., Bahur, B., Bray, K. R., Gecse, K. B., & D'Haens, G. R. (2025). Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf101
Vancouver
Teichert C, Anjie SI, Stevens TW, Bahur B, Bray KR, Gecse KB, et al. Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf101
BibTeX
@article{Teichert2025,
author = {Teichert, Christoph and Anjie, Suzanne I and Stevens, Toer W and Bahur, Bayda and Bray, Kurtis R and Gecse, Krisztina B and D'Haens, Geert R},
title = {Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf101}
}
EUVIMED